In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Globus Medical, Inc. has a 12 month low of $49.33 and a 12 month high of $94.93. The stock has a fifty day simple moving average of $85.85 and a two-hundred day simple moving average of $77.36.

Globus Medical (NYSE:GMED – Get Free Report) last announced its earnings results on Tuesday, November 5th.The medical device company reported $0.83 earnings per share (EPS) for the quarter ...

AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full ...

Analyst Ryan Zimmerman from BTIG maintained a Buy rating on Globus Medical (GMED – Research Report) and keeping the price target at $91.00. Ryan Zimmerman’s rating is based on a combination of ...

Globus Medical GMED has seen impressive momentum in the past year, with its shares soaring 62.1%. It has significantly outperformed the industry’s 7.3% rise and the S&P 500 composite’s 24.8% gain.

Audubon, PA-based Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its ...

The average surprise for the last two quarters was 18.99%. For the last reported quarter, Globus Medical came out with earnings of $0.83 per share versus the Zacks Consensus Estimate of $0.65 per ...